跳到主要导航
跳到搜索
跳到主要内容
Pure University (For Demo Only) 国内
帮助和常见问题
English
中文
国内
简介
研究单位
科研成果
设备
数据集
活动
奖项
影响
项目
新闻 / 媒体
按专业知识、名称或附属进行搜索
Treatment pathways in an inception lupus cohort over the first three years
J. G. Hanly
, A. Sayani,
S. Doucette
, S. Iczkovitz, J. A.Ross Terres
科研成果
:
期刊稿件
›
文章
›
同行评审
5
引用 (Scopus)
综述
指纹
指纹
探究 'Treatment pathways in an inception lupus cohort over the first three years' 的科研主题。它们共同构成独一无二的指纹。
分类
加权
按字母排序
Keyphrases
Lupus
100%
Treatment Pathways
100%
Corticosteroids
100%
Systemic Lupus Erythematosus
33%
SLE Disease Activity Index (SLEDAI)
25%
American College of Rheumatology
16%
Cumulative Dose
16%
Systemic Lupus Erythematosus Patient
16%
New Onset
16%
Descriptive Statistics
8%
Well-defined
8%
Patient Demographics
8%
Mixed Models
8%
Rheumatic Diseases
8%
Damage Index
8%
Inception Cohort
8%
Systemic Lupus International Collaborating Clinics
8%
High Disease Activity
8%
Disease Activity Score
8%
Disease Duration
8%
Treatment Algorithm
8%
Daily Dose
8%
Classification Criteria
8%
Treatment Patterns
8%
Medicine and Dentistry
Systemic Lupus Erythematosus
100%
Lupus Erythematosus
100%
Immunosuppressant
66%
Antimalarial Agent
66%
SLEDAI
50%
Rheumatology
33%
Disease
16%
Drug Therapy
16%
Mixed Model
16%
Rheumatic Disease
16%
Disease Activity
16%
Disease Activity Score
16%
Disease Duration
16%
Pharmacology, Toxicology and Pharmaceutical Science
Systemic Lupus Erythematosus
100%
Immunosuppressive Agent
44%
Disease Activity
44%
Antimalarial Agent
44%
Disease
11%
Rheumatic Disease
11%
Mixed Model
11%
Disease Duration
11%
Disease Activity Score
11%
Neuroscience
Systemic Lupus Erythematosus
100%
Lupus Erythematosus
100%
Antimalarial Agent
44%
Rheumatology
22%
Immunology and Microbiology
Lupus Erythematosus
100%
Systemic Lupus Erythematosus
100%
Antimalarial Agent
44%
Rheumatic Disease
11%
Psychology
Systemic Lupus Erythematosus
100%
Lupus Erythematosus
100%
Mixed Model
14%
Rheumatic Disorder
14%